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The current paradigm suggests that some non-BRCA1/2
multiple case breast cancer families are caused by rare
mutations in high-risk genes. We are using exome
sequencing to identify putative ‘BRCA3’ genes in a small
number of kConFab families. We selected five non-
BRCA1/2 families containing 5-9 breast cancer cases (of
which 0-4 per family were affected under the age of 40)
who have had extensive analysis of BRCA1 and BRCA2,
and for which germline DNA was available from two
distant relatives (at least 4
th degree) affected with breast
cancer between 30 and 56 years of age. In first stage we
isolated the exomes of two pairs of affected individuals
(4
th and 5
th degree relatives, from two families) diag-
nosed with breast cancer between the age of 30 and 39,
using the SeqCap EZ exome capture kit (NimbleGen)
and then sequenced the libraries on the GAIIx and
HiSeq (Illumina) platforms with a paired-end protocol.
The sequences were aligned to the human genome with
BWA and we then compared several pipelines for pro-
cessing the sequences and calling variants. The best
results were obtained with the Picard/GATK pipeline
after local re-alignment and re-calibration of the base
quality. The samples from the remaining three families
will be sequenced by Axeq Inc. and the results of the
analysis will be presented.
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